RxDoctor Payments DataLook up a doctor →

Vamsi Krishna, MD

Interventional Cardiology · Kyle, TXNPI 1891930863

Payments from drug & device makers

$2,152,856in general payments, 2019–2025

Across 3,294 payments — averaging $653.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$518K
  • Shockwave Medical, Inc$426K
  • Abbott$195K
  • Terumo Medical Corporation$147K
  • Novo Nordisk$145K
  • Amgen$127K
  • plus $595K from 54 others
$10,387in research payments, 2019–2025

Across 1 payment — averaging $10,387 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inspiremd Ltd$10K

What the payments were for

  • Consulting fees$455,27823%
  • Speaking & faculty fees$1,265,93364%
  • Travel & lodging$149,0308%
  • Food & beverage$93,1595%
  • Education$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson539$518,297
Shockwave Medical, Inc318$425,618
Abbott407$195,462
Terumo Medical Corporation170$146,923
Novo Nordisk159$144,702
Amgen184$126,941
Medtronic(2 entities)163$100,812
Lilly USA, LLC82$77,366
Janssen Research & Development, LLC53$77,298
Scpharmaceuticals Inc.106$67,248
AstraZeneca106$50,772
Cook Incorporated11$38,080
Cardiovascular Systems Inc.92$29,639
Philips North America LLC145$26,326
Inari Medical, Inc.93$25,729
Atricure, Inc.27$22,542
Cardinal Health 200 LLC11$14,766
Biotronik Inc.103$10,706
Siemens Medical Solutions USA, Inc.22$10,561
Acist Medical Systems, Inc.13$10,146
Heartflow, Inc.15$8,742
Cook Medical LLC71$5,037
Boston Scientific31$3,389
Bayer6$2,964
Reflow Medical Inc15$2,409
Novartis110$1,726
Penumbra, Inc.22$894
Abiomed15$722
Corindus Inc.5$680
Teleflex LLC9$586
Bard Peripheral Vascular, Inc.15$574
Biosense Webster, Inc.15$554
Amarin Pharma, Inc.40$466
Tactile Systems Technology Inc26$406
Irhythm Technologies, Inc.6$378
Impulse Dynamics (USA) Inc.6$359
Esperion Therapeutics, Inc.21$285
Recor Medical Inc3$239
Haemonetics Corporation11$237
Avinger Inc.2$227
Surmodics, Inc.3$223
EKOS Corporation2$218
Osprey Medical Inc2$206
Baylis Medical Technologies Inc.1$200
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$169
Cordis US CORP.2$159
W. L. Gore & Associates, Inc.1$158
E.r. Squibb & Sons, L.L.C.10$141
Stryker3$95
Z-medica, LLC4$83
Angiodynamics, Inc.2$57
Veryan Medical Incorporated1$47
Cvrx, Inc.1$47
Foundation Fusion Solutions, LLC1$47
BD2$42
Edwards Lifesciences1$39
Kiniksa Pharmaceuticals International, PLC2$36
Kestra Medical Technology Services, Inc.2$33
Pfizer1$16
Mannkind Corporation1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,152,856 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$284,820
Medicare patients
615
Services billed
2,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban344$383,626
OzempicSemaglutide241$364,762
Repatha SureclickEvolocumab248$279,638
EntrestoSacubitril/Valsartan180$219,417
EliquisApixaban169$201,598
MounjaroTirzepatide149$189,033
Repatha PushtronexEvolocumab183$180,458
FuroscixFurosemide26$125,944
FarxigaDapagliflozin Propanediol98$95,314
BrilintaTicagrelor67$68,301
JardianceEmpagliflozin55$59,577
WegovySemaglutide28$46,909
Praluent PenAlirocumab42$40,622
VascepaIcosapent Ethyl71$40,089
Ezetimibe893$23,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$144,702$411,671269 claims
Johnson & JohnsonXarelto$518,297$383,626344 claims
NovartisEntresto$1,726$219,417180 claims
Lilly USA, LLCMounjaro, Trulicity$77,366$207,331160 claims
PfizerEliquis$16$201,598169 claims
AstraZenecaFarxiga, Brilinta$50,772$163,615165 claims
Scpharmaceuticals Inc.Furoscix$67,248$125,94426 claims
Esperion Therapeutics, Inc.Nexlizet$285$17,66817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Kyle

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →